Article Text

PDF
Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
  1. L B Cantor,
  2. J Hoop,
  3. L Morgan,
  4. D WuDunn,
  5. Y Catoira,
  6. The Bimatoprost–Travoprost Study Group
  1. Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA
  1. Correspondence to: L B Cantor Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA;lcantor{at}iupui.edu

Abstract

Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension.

Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months.

Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p⩾0.741). After 6 months, both drugs significantly reduced IOP at every time point (p⩽0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups.

Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

  • IOP, intraocular pressure
  • OAG, open-angle glaucoma
  • OHT, ocular hypertension

Statistics from Altmetric.com

Footnotes

  • Published Online First 6 July 2006

  • The Bimatoprost–Travoprost Study Group included: Thomas Bournias, Northwestern University, Chicago, Illinois; Louis Cantor, Indiana University School of Medicine, Indianapolis, Indiana; Monte Dirks, Black Hills Regional Eye Institute, Rapid City, South Dakota; Efraim Duzman, Lakeside Vision Center, Irvine, California; Arash Mansouri, Access Eye Centers, Fredericksburg, Virginia; Thomas Mundorf, Mundorf Eye Center, Charlotte, North Carolina; Steven Simmons, Glaucoma Consultants of the Capital Region, Slingerlands, New York; Robert Williams, Taustine Eye Center, Louisville, Kentucky.

  • Funding: This study was supported by an unrestricted educational grant from Allergan, Irvine, California, USA.

  • Competing interests: Dr Cantor is a consultant for and has received speaker honoraria from Allergan, and research support from Allergan, Alcon and Pfizer. Dr WuDunn is a consultant for and has received speaker honoraria from Alcon and research support from Alcon and Pfizer. Dr Catoira has received speaker honoraria from Allergan and Pfizer.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles